



Population data in thousands ¹								
	2018	2017	2016	2015	2014	2000	1990	1980
Total population	1'982'238	1'962'281	1'942'091	1'921'673	1'901'046	1'572'822	1'313'773	1'056'328
Live births	34'906	35'035	35'184	35'375	35'633	39'660	39'621	37'632
Surviving infants	33'919	34'006	34'109	34'249	34'449	37'263	36'347	33'606
Pop. less than 5 years	169'880	170'209	171'159	172'999	174'725	182'811	177'792	157'298
Pop. less than 15 years	527'363	530'284	533'281	536'532	539'349	530'812	493'457	421'843
Female 15-49 years	1'072'393	1'060'994	1'049'055	1'036'464	1'024'106	826'090	653'743	507'388
Number of reported cases								
Diphtheria	10'299	7'053	4'016	2'504	7'666	5'470	11'582	47'354
Japanese encephalitis	2'035	2'909	3'500	2'831	3'320	-	-	-
Measles	34'741	28'474	27'530	48'888	42'899	78'558	224'925	199'535
Mumps	32'018	61'783	31'739	42'937	38'327	9'395	-	-
Pertussis	17'532	33'976	43'141	29'813	54'953	38'510	156'028	399'310
Polio	1	0	0	2	0	591	11'313	20'089
Rubella	4'533	4'386	10'361	6'515	9'690	1'165	-	-
Rubella (CRS)	342	754	319	183	86	26	-	-
Tetanus (neonatal)	252	443	399	983	658	4'322	11'725	3'149
Tetanus (total)	7'712	6'829	5'771	3'806	7'099	11'554	35'452	62'176
Yellow fever	0	0	0	0	0	0	-	-
Percentage of target population vaccinated, by antigen								
<i>based on WHO-UNICEF estimates</i>								
<i>TT2plus is based on reported coverage</i>								
BCG	91	92	89	88	90	78	71	12
DTP1	92	92	91	91	90	78	87	22
DTP3	89	89	88	87	86	64	70	7
HepB_BD	48	45	34	31	29	0	-	-
HepB3	89	89	88	87	82	10	0	-
Hib3	87	87	80	56	32	0	0	-
IPV1	74	46	38	7	-	-	-	-
MCV1	89	89	88	87	85	63	59	0
MCV2	80	79	75	66	59	3	-	-
PCV3	17	12	9	4	0	-	-	-
Pol3	89	89	87	87	85	64	67	3
RCV1	83	21	15	15	13	3	0	0
rotac	24	9	3	0	0	-	-	-
TT2plus	78	82	77	78	71	81	74	18

Most countries have standard recommendations regarding which vaccines should be offered and at what ages they should be given. In general, vaccines are recommend for the youngest age group at risk for developing the disease whose members are known to respond to the immunization without adverse effects.

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV). IPV global and regional coverage calculation is for 144 bOPV using countries.

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.

1) "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.